Biotech Daily

Thursday August 21, 2025

Daily news on ASX-listed biotechnology companies

*** ASX, BIOTECH UP: CURVEBEAM UP 21%; ATOMO DOWN 10%**

*** TELIX H1 REVENUE UP 63% TO $607m; PROFIT DOWN 87% TO $5m**

*** MEDICAL DEVELOPMENTS REVENUE UP 18% TO $39m; LOSS TO $94k PROFIT**

*** IDT REVENUE UP 41% TO $20m; LOSS UP 49% TO $8m**

*** FISHER & PAYKEL EXPECTS H1 REVENUE OF $1.2b, $221m PROFIT**

*** FDA CLEARS ARTRYA SALIX CORONARY PLAQUE MODULE**

*** VICTORIA $17.5m FOR 'VELOS' MONASH HEART RESEARCH HUB**

*** QUEENSLAND UNI: 'WORLD 1st HUMAN SKIN GROWN IN LAB'**

*** ATOMO, LUMOS PASCAL FOR FEBRIDX SUPPLY DISCUSSIONS**

*** BLINKLAB: PENNSYLVANIA UNI JOINS US DX1 AUTISM TRIAL**

*** TRYPTAMINE TO PAY $155k FOR TRP-8803 BIOMARKER EEG**

*** MEDADVISOR EGM 74% BLOCK MANAGEMENT 'RETENTION BENEFITS'**

*** WESTPAC REDUCES, DILUTED TO 5% OF PACIFIC EDGE**

*** MELBOURNE SECURITIES, BV1 FUND BELOW 5% OF HERAMED**

*** FISHER & PAYKEL TO LOSE DIRECTOR PIP GREENWOOD**

*** LITTLE GREEN LOSES 6-MONTH DIRECTOR DAVID FENLON**

MARKET REPORT

The Australian stock market was up 1.13 percent on Thursday August 21, 2025, with the ASX200 up 101.1 points to 9,019.1 points. Twenty-four of the Biotech Daily Top 40 companies were up, nine fell, six traded unchanged and one was untraded.

Curvebeam was the best, up three cents or 20.7 percent to 17.5 cents, with 1.1 million shares traded. Actinogen climbed 11.1 percent; Resonance and Telix rose seven percent or more; 4D Medical and Cynata were up more than six percent; Alcidion and Cyclopharm improved five percent or more; Medadvisor, Optiscan, Paradigm, Starpharma and Syntara were up more than three percent; Clarity, Clinuvel, CSL, EBR, Mesoblast and Neuren rose more than two percent; Imugene, Nanosonics, Polynovo and Resmed were up more than one percent; with Aroa, Cochlear, Orthocell and SDI up by less than one percent.

Atomo led the falls, down 0.2 cents or 10.0 percent to 1.8 cents, with 4.2 million shares traded. Genetic Signatures fell 4.8 percent; Medical Developments lost 3.15 percent; Micro-X shed 2.4 percent; Avita, Dimerix, Emvision, Nova Eye and Proteomics were down more than one percent; with Pro Medicus down 0.2 percent.

TELIX PHARMACEUTICALS

Telix says revenue for the six months to June 30, 2025 was up 62.9 percent to $US390,359,000 ($A607,416,000), with net profit after tax down 87.3 percent to $US3,255,000 ($A5,065,000).

Earlier this month, Telix fell as much as 20.95 percent after it voluntarily released an "unaudited recast of its historical financial information in US dollars following a change in reporting currency from Australian dollars" (BD: Feb 25, Aug 5, 2025).

Today, the company said revenue from sales of its Illuccix prostate cancer imaging kit was $US305.8 million, with $US79.0 million attributable to sales of third-party products and services following its acquisition of RLS Radiopharmacies.

In January, the company said it had completed its acquisition of the Orlando, Florida-based RLS Inc Radiopharmacies network for up-to $US250 million (BD: Jan 28, 2025).

Today, Telix said its reduced profit reflected "the impact of finance costs on convertible bonds issued in July 2024 and increased investment in the phase III 'Prostact' global trial", with research and development expenditure for the six months up 47.3 percent to $US81.6 million, or 20.9 percent of revenue.

Telix managing-director Dr Christian Behrenbruch said the company continued "to deliver strong revenue growth while building a foundation for the future".

"The first half of 2025 was a period of rapid transformation as we expanded our global manufacturing operations, invested in launching new products in new markets, and accelerated the development of our therapeutic pipeline," Dr Behrenbruch said.

"These investments have positioned Telix for sustainable, long-term growth, while our diversified business provides multiple drivers of success," Dr Behrenbruch said.

"To generate future revenue growth, we are confident in securing product approvals for Pixclara and Zircaix while advancing geographic and indication expansion for the [prostate specific membrane antigen] portfolio," Dr Behrenbruch said.

The company said last year's diluted earnings per share of 5.98 US cents a share was turned to a diluted loss per share of 0.68 US cents, and negative net tangible assets per share were up 955.1 percent to negative 68.37 US cents.

Telix said it had cash and cash equivalents of $US207,156,000 at June 30, 2025, compared to $US79,011,000 at June 30, 2024.

Telix was up $1.18 or seven percent to $18.10 with 4.7 million shares traded.

MEDICAL DEVELOPMENTS INTERNATIONAL

Medical Developments says revenue for the year to June 30, 2025 rose 17.8 percent to $39,056,000, with last year's $40,992,000 loss turned to a $94,000 net profit after tax.

Medical Developments said revenue for its Penthrox inhaled methoxyflurane analgesic and other pain management products was up 23.0 percent to $26,190,000, with sales of its respiratory products, including asthma spacers, up 8.5 percent to $12,866,000.

Last year, the company said it had incurred $5.1 million in share-based payment expenses for the cancellation of options as part of chief executive officer Brent MacGregor's remuneration, as well as $15.8 million in one-off impairment costs and $600,000 in costs related to "redundant plant and equipment" (BD: Aug 26, 2024).

Today, Medical Developments said it had diluted earnings per share of 0.08 cents for the year compared to a diluted loss per share of 47.50 cents in the prior year.

The company said net tangible asset backing per share rose 11.3 percent to 29.5 cents.

Medical Developments said it had cash of $17,837,000 at June 30, 2025 compared to $9,735,000 at June 30, 2024.

Medical Developments fell two cents or 3.15 percent to 61.5 cents.

IDT AUSTRALIA

IDT says revenue for the year to June 30, 2025 was up 40.6 percent to $19,861,000, with net loss after tax up 49.0 percent to $8,063,000.
IDT said revenue was for its manufacturing services for pharmaceuticals including specialty oral products, medical marijuana and psychedelics, as well as active pharmaceutical ingredients and advanced therapies.
The company said its loss included “the recognition of bad debts of circa $1.2 million relating to two customers defaulting on payments in 2024-’25”.
IDT said it was “working towards a positive cashflow and profitability position, while growing core revenue from its three verticals in the current financial year”, with revenue expected to be driven by advanced therapies, including antibody drug conjugates and messenger RNA treatments and a shortage of drug making facilities.
IDT said diluted loss per share rose 21.9 percent to 1.89 cents, net tangible assets per share fell 23.7 percent to 5.09 cents, with cash and equivalents of $503,000 at June 30, 2025 compared to $504,000 at June 30, 2024.
IDT was up 0.1 cents or 1.45 percent to seven cents.

FISHER & PAYKEL HEALTHCARE CORP

Fisher & Paykel says it expects revenue for the six months to September 30, 2025 of $NZ1,075 million ($A1,186 million) with net profit after tax of $NZ200 million.
Fisher & Paykel said it expected full-year guidance to be unchanged with revenue to March 31, 2026 of $NZ2.15 billion and $NZ2.25 billion, and net profit after tax of $NZ390 million to $NZ440 million for the year to
In May, Fisher & Paykel said revenue from its at-home and surgical products for chronic respiratory care including sleep apnoea for the year to March 31, 2025 was $NZ2,021,000,000, with net profit after tax of $NZ377,200,000 (BD: May 28, 2025).
Today, the company said its guidance included “an estimated 75-basis point impact of US tariffs on hospital products sourced from New Zealand” and assumed “current global tariff rates, policies and applications for the duration of this financial year”.
Fisher & Paykel was up 45 cents or 1.3 percent to $34.72 with 567,567 shares traded.

ARTRYA

Artrya says it has US Food and Drug Administration 510(k) clearance for its Salix coronary plaque module for detecting high-risk plaque, an indicator of heart disease.
Earlier this year, Artrya said it had FDA 510(k) clearance to commercialize its Salix coronary anatomy platform (BD: Mar 28, 2025).
Today, Artrya said the coronary plaque module was “already embedded within the same user interface as the Salix coronary anatomy platform and can immediately be enabled in the live version of the platform following this FDA clearance”.
The company said this made “the expanded Salix technology … available to clinicians, with assessments available to them in less than 10 minutes and without changing or using multiple systems, as required with competing technology”.
Artrya chief executive officer John Konstantopoulos said the company was “thrilled to have received FDA clearance of our Salix coronary plaque module, which opens up a much greater revenue opportunity for us in the US, our largest market”.
Mr Konstantopoulos said Salix customers could “receive an attractive category 1 reimbursement of $US9,502 ($A14,800) for each plaque assessment they perform”.
Artrya was up 49 cents or 37.7 percent to $1.79 with 5.8 million shares traded.

VICTORIA GOVERNMENT, MONASH UNIVERSITY

The Victoria Government says it has provided $17.5 million for Monash University to open the 'Monash Velos Accelerator' cardiovascular disease research centre.

A media release from the Victoria Minister for Water and Minister for Skills and TAFE Gayle Tierney said the centre was opened yesterday and located at Monash University's Technology Precinct in Clayton, Melbourne.

The Victoria Government said the hub would work with the Victorian Heart Hospital and Victorian Heart Institute and "fast-track heart health therapies, clinical products, cardiac technology and … models of care, focusing on the connections between obesity, diabetes, chronic kidney disease and cardiovascular disease".

The Government said the centre included "research and collaboration spaces for start-ups, industry and manufacturers, with access to cutting-edge equipment and technology to help drive the invention and commercialization of new health care products and services".

The Victoria Government said the 'Velos Accelerator' would "develop training and education programs in partnership with industry … to build the capability for entrepreneurship within the clinical and research workforce and deliver the health solutions our state needs sooner".

The Government said the centre was jointly funded by Monash University and would be an "innovation hub, addressing some of the most pressing global health challenges".

UNIVERSITY OF QUEENSLAND

The University of Queensland says its researchers are "the first in the world to successfully grow fully-functioning human skin in a laboratory".

The University said it used stem cells to create a 3-dimensional replica of human skin in a laboratory model "complete with blood vessels, capillaries, hair follicles, layers of tissue and immune cells".

The University of Queensland said the research, titled 'Coordinated Development of Immune Cell Populations in Vascularized Skin Organoids from Human Induced Pluripotent Stem Cells' was published in Wiley Advanced Healthcare Materials, with the full article available at: http://bit.ly/4fMpJaz.

The University said the study was with Brisbane's North Health Metro and that engineered skin could "help improve skin graft transplants and treatments for inflammatory skin disorders such as psoriasis, atopic dermatitis, scleroderma and other genetic diseases".

Co-author Dr Abbas Shafiee said the skin model was "six years in the making [and] would be transformative for skin graft transplants, wound healing, and studying skin disorders".

"This is the most life-like skin model that's been developed anywhere in the world and will allow us to study diseases and test treatments more accurately," Dr Shafiee said.

"Until now, scientists have been limited in how we study skin diseases and develop new therapies," Dr Shafiee said. "But with a skin model like this, that closely mimics real human skin, we will be able to study diseases more closely, test treatments and develop new therapies more effectively."

Dr Shafiee said the research team took human skin cells and reprogrammed them into stem cells, placed those stem cells into petri dishes and grew them into mini versions of skin, called skin organoids and then used the same stem cells to create tiny blood vessels and added these to the growing skin.

"It developed just like natural human skin, with layers, hair follicles, pigmentation, appendage patterning, nerves, and most importantly, its own blood supply," Dr Shafiee said.

ATOMO DIAGNOSITCS

Atomo says it is in discussions about the supply of its Pascal cassettes for Lumos' Febridx finger-prick blood test under Lumos' contract with Phase Scientific.
Last month, Lumos said it had an up-to $US317 million ($A487 million), six-year distribution and supply deal with Hong Kong's Phase Scientific International Ltd for its Febridx test, subject to a US Food and Drug Administration clinical laboratory improvement amendments (CLIA)-waiver (BD: Jul 17, 2025).
Earlier this month, Atomo said it had a $US410,000 order for its Pascal cassettes from Lumos "to support scale-up of Febridx demand in the US" (BD: Aug 7, 2025).
On Monday, Lumos said it had filed a CLIA-waiver with the US Food and Drug Administration for Febridx finger-prick blood test for differentiating between viral and bacterial respiratory infections (BD: Aug 18, 2025).
At that time, Lumos said its 800-patient study of Febridx showed "a 99.1 percent concordance between trained and untrained operators testing bacterial positive patients, and a 98.4 percent concordance for non-bacterial patients," meaning that the test poised insignificant risk of erroneous results in the hands of untrained users.
Today, Atomo said it was "extremely pleased" that in the CLIA-waiver trial Pascal enabled more than 99 percent agreement between trained and untrained operators using Febridx.
Atomo managing-director John Kelly said the company was "very pleased to see demand for Pascal in a valuable long-term contract in the US market".
Atomo fell 0.2 cents or 10 percent to 1.8 cents with 4.2 million shares traded.

BLINKLAB

Blinklab says Philadelphia's University of Pennsylvania will be the third site for its US Food and Drug Administration 510(k) trial of its Dx1 diagnostic for autism.
In June, Blinklab said it had ethics approval for the 1,000-patient, main study of its US diagnostic trial of its Dx1 smartphone application for autism (BD: Jun 30, 2025).
Last month, the company said Omaha's University of Nebraska Medical Centre would be the second site for the trial (BD: Jul 8, 2025).
Today, Blinklab said the study was expected to be completed by July, with final FDA submission expected by October, 2026.
Blinklab fell two cents or 3.9 percent to 49 cents.

TRYPTAMINE THERAPEUTICS (FORMERLY EXOPHARM)

Tryptamine says it will pay $US100,000 ($A155,000) to develop an electro-encephalogram (EEG) biomarker platform for its TRP-8803 intra-venous (I-V) psilocin.
Tryptamine said it had a one-year agreement with two researchers from Imperial College London, Prof Robin Carhart-Harris and Prof Pedro Mediano, to develop the EEG platform, which would use "real-time cortical entropy to predict and optimize therapeutic outcomes before, during and after [intra-venous] administration of TRP-8803".
Previously, the company said that psilocin was the active psychedelic metabolite of psilocybin found in 'magic mushrooms' (BD: Jul 1, 2024).
Today, the company said central nervous system active treatments using biomarkers had "more than a 10-fold higher probability" of achieving regulatory approval.
Tryptamine said the contract could be extended for a further year and it would grant 1,000,000 options, each, to Prof Carhart-Harris and Prof Mediano, exercisable at eight cents each within two years, subject to shareholder approval.
Tryptamine was up 0.1 cents or three percent to 3.4 cents.

MEDADVISOR

Medadvisor says its extraordinary general meeting has defeated six resolutions to issue retention benefits to its management, with up-to 73.51 percent opposition.

Earlier this month, Medadvisor said it had completed the $35 million sale of its Australia and New Zealand business operations to Brisbane's Jonas Software Aus Pty Ltd and repaid its $US15.1 million ($A23 million) finance facilities (BD: Jul 7, 2025).

Last month, the company said investors would vote to issue about $2,070,000 in retention benefits to managing-director Richard Ratliff, chief financial officer Ancila Desai and chief operating officer Vinod Subramanian, as well as 2,182,540 incentive options to Mr Ratliff (BD: Jul 22, 2025).

Today, Medadvisor said the issue of retention benefits to Mr Ratliff was opposed by 267,677,223 votes (73.51%), with 96,478,371 votes (26.49%) in favor.

The company said Ms Desai and Mr Subramanian's retention benefits were defeated by between 59.12 percent and 59.24 percent of the meeting.

Medadvisor said the ratification of the issue of placement shares and options were passed with 35.94 percent and 28.94 percent opposition, with Mr Ratliff's options approved by 80.65 percent of votes.

The company said the remaining resolutions were all passed more easily, with more than 98.84 percent of the meeting in favor.

According to its most recent filing, Medadvisor had 625,254,103 shares on issue, meaning that the 267,677,223 votes against Mr Ratliff's retention benefits amounted to about 42.8 percent of the company, sufficient to call extraordinary general meetings.

Medadvisor was up 0.2 cents or 3.45 percent to six cents.

PACIFIC EDGE

Westpac Banking Corporation says it has increased its holding in Pacific Edge to 53,678,435 shares, and been diluted from 6.70 percent to 5.25 percent.

The Sydney-based Westpac said that it bought 500,000 shares on August 13, 2025 for $NZ50,000, or 10 NZ cents (9.1 Australian cents) a share.

Earlier this month, Pacific Edge said it raised $NZ20.7 million at 10 NZ cents a share in a $NZ16.1 million placement and $NZ4.7 million share plan (BD: Aug 4, 2025).

According to its last substantial shareholder notice lodged to the New Zealand Stock Exchange dated September 29, 2021, Westpac held 52,810,384 shares, or 6.70 percent of Pacific Edge.

Pacific Edge was untraded at nine cents.

HERAMED

Melbourne Securities Corp as trustee for BV1 Fund says it has ceased its substantial shareholding in Heramed.

Melbourne Securities Corp said that it bought and sold shares between July 12, 2024 and June 3, 2025 and was diluted by a placement on August 13, 2025.

Earlier this month, Heramed said it had "commitments" to raise $1.98 million at 1.2 cents a share in a placement, with 1.0 quarters of cash (BD: Aug 4, 2025).

Heramed was up 0.3 cents or 12.0 percent to 2.8 cents with 1.4 million shares traded.

FISHER & PAYKEL HEALTHCARE CORP

Fisher & Paykel says director Pip Greenwood has announced her intention to retire from the board, effective from September 1, 2025.
Fisher & Paykel said Ms Greenwood had been a director since June 2017, was recently appointed to the board of Westpac Banking Australia and was chair of A2 Milk and Westpac Banking New Zealand.
The company thanked Ms Greenwood for her “significant contribution”.
Fisher & Paykel chair Neville Mitchell said the company would appoint a replacement director.

LITTLE GREEN PHARMA

Little Green Pharma says David Fenlon will retire from the board due to personal reasons and other commitments, effective from its annual general meeting today.
Little Green said it had withdrawn annual general meeting resolutions to elect Mr Fenlon and issue him 150,000 non-executive retention rights.
The company said it thanked Mr Fenlon for his time and contribution as a director.
In March, Little Green said Mr Fenlon would replace Beatriz Vicén Banzo as a non-executive director (BD: Mar 3, 2025).
Little Green fell 0.25 cents or 2.2 percent to 11.25 cents.